Admission Date:  [**2172-12-20**]              Discharge Date:   [**2172-12-23**]  Date of Birth:  [**2107-8-3**]             Sex:   F  Service: MEDICINE  Allergies: Rituximab / Vincristine / Penicillins  Attending:[**First Name3 (LF) 2485**] Chief Complaint: Rituximab desensitization.
Given the level of thrombocytopenia her treatment regimen is limited to Rituximab.
Specifically she received her first dose in [**2168**] and she was noted to have chills, HTN, rigors, sense of doom within an hour of infusion which was relived when the infusion was stopped.
She underwent a retrial of Rituximab in [**2170**] with a slower rate of infusion, unfortunately she had the sensation of throat tightening and itching and the infusion was stopped.
She underwent another retrial several weeks ago with pretreatment of steroids, Benadryl and unfortunately she was noted to have rigors, chills, HTN, throat itching and ?swelling within an hour of infusion.
Per allergy their consensus is this is a complement mediated reaction and they recommend 48hours of IV Methylprednisolone 40mg IV q6hours.
She was started on R-CHOP but given her aforementioned reactions she received 6 cycles of CHOP, completing in [**2170-2-22**] and achieving a complete remission as documented by PET-CT on [**2170-4-13**].
She relapsed by CT scan in [**2171-2-23**] and received one cycle of fludarabine 50mg daily on days [**12-29**].
This treatment was complicated by febrile neutropenia and was discontinued.
She then underwent six cycles of CVP, complicated by neuropathy.
She underwent a bone marrow bx on [**10/2172**] given persistent thrombocytopenia.
She was started on chlorambucil 4mg daily on approximately [**2172-11-13**] which was complicated by leukopenia and admission for anemia two weeks later.
woman with follicular lymphoma and pancytopenia admitted to ICU for Rituximab desensitization.
Given her thrombocytopenia and adverse effects on other regimens pt was admitted for Rituximab desensitization.
She was originally admitted to the BMT floor and then transferred to the [**Hospital Unit Name 153**] for close airway monitoring given her prior reactions to Rituximab of throat itchiness, HTN, rigors.
She was seen by Allergy who recommended a desensitization protocol of 48hrs of Methylprednisolone 40mg q6hr followed by H2 blocker, Benadryl with desensitization goal dose of 600mg.
On the BMT floor she received 2u of PRBC and 1u plts.
She will need to follow up with her oncologist for her bone marrow biopsy results for MDS.
BOOP: She was continued on her home regimen of Symbicort.
Peripheral Neuropathy: Attributed to Vincristine exposure, she was continued on her home regimen of Gabapentin.
Hyperlipidemia: She was continued on home regimen of Simvastatin.
Hypothyroidism: She was continued on home regimen of levothyroxine.
Medications on Admission: BUDESONIDE-FORMOTEROL [SYMBICORT] - (Prescribed by Other Provider) - Dosage uncertain EPOETIN ALFA [EPOGEN] - (Prescribed by Other Provider) - 40,000  unit/mL Solution - 60,000 units q7d GABAPENTIN - (Prescribed by Other Provider) - 100 mg Capsule - 2  Capsule(s) by mouth twice a day LEVOTHYROXINE - (Prescribed by Other Provider) - 50 mcg Tablet -  1 Tablet(s) by mouth once a day LORAZEPAM - (Prescribed by Other Provider) - Dosage uncertain SIMVASTATIN - (Prescribed by Other Provider) - 20 mg Tablet - 1  Tablet(s) by mouth once a day Medications - OTC CALCIUM - (Prescribed by Other Provider) - Dosage uncertain DOCUSATE SODIUM [COLACE] - (Prescribed by Other Provider) - Dosage uncertain MULTIVITAMIN - (Prescribed by Other Provider) - Dosage uncertain    Discharge Medications: 1.
Gabapentin 100 mg Capsule Sig: Two (2) Capsule PO BID (2 times a day).
Symbicort 160-4.5 mcg/Actuation HFA Aerosol Inhaler Sig: Two (2) puffs Inhalation [**Hospital1 **] ().
Epogen 20,000 unit/mL Solution Sig: 60,000 units Injection once a week.
Levothyroxine 50 mcg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Simvastatin 10 mg Tablet Sig: Two (2) Tablet PO DAILY (Daily).
Multivitamin     Capsule Sig: One (1) Capsule PO once a day.
Discharge Disposition: Home  Discharge Diagnosis: Primary: Rituximab desensitization Secondary: Pancytopenia, Anemia requiring blood transfusion, Neutropenia   Discharge Condition: Mental Status:Clear and coherent Level of Consciousness:Alert and interactive Activity Status:Ambulatory - Independent   Discharge Instructions: You were admitted to the hospital for the initiation of the Rituximab medication for your Follicular Lyphoma.
As your blood and platelet counts were low you were also given blood and platelet transfusions.
